Antiamyloidantistoffer til behandling af Alzheimers sygdom i tidlige sygdomsstadier

Kristian Steen Frederiksen; Mathias Holsey Gramkow; Steen G Hasselbalch; Ian Law; Gunhild Waldemar

doi:10.61409/V03250217

Antiamyloidantistoffer til behandling af Alzheimers sygdom i tidlige sygdomsstadier

Kristian Steen Frederiksen, Mathias Holsey Gramkow, Steen G Hasselbalch, Ian Law, Gunhild Waldemar

Abstract

Alzheimer's disease is the most common neurodegenerative dementia disorder and is associated with several negative health outcomes. Current treatment consists of symptomatic treatment and supportive measures. However, advances have led to the development of antibodies towards beta-amyloid, which likely plays a pivotal role in the pathophysiology. Lecanemab and donanemab have shown efficacy in the early stages of Alzheimer's disease but are also associated with a risk of cerebral haemorrhages and oedema. The introduction of these antibodies will require adjustment of diagnostic and management pathways as discussed in this review.

Bidragets oversatte titel	Anti-amyloid antibodies for the treatment of early-stage Alzheimer's disease
Originalsprog	Dansk
Artikelnummer	V03250217
Tidsskrift	Ugeskrift for Laeger
Vol/bind	187
Udgave nummer	35
ISSN	0041-5782
DOI	https://doi.org/10.61409/V03250217
Status	Udgivet - 25 aug. 2025

Emneord

Humans
Alzheimer Disease/drug therapy
Amyloid beta-Peptides/immunology
Antibodies, Monoclonal, Humanized/therapeutic use
Antibodies, Monoclonal/therapeutic use

Adgang til dokumentet

10.61409/V03250217Licens: CC BY-NC-ND

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{fe536ac68bc8433bbb5b3ee1da36ae59,

title = "Antiamyloidantistoffer til behandling af Alzheimers sygdom i tidlige sygdomsstadier",

abstract = "Alzheimer's disease is the most common neurodegenerative dementia disorder and is associated with several negative health outcomes. Current treatment consists of symptomatic treatment and supportive measures. However, advances have led to the development of antibodies towards beta-amyloid, which likely plays a pivotal role in the pathophysiology. Lecanemab and donanemab have shown efficacy in the early stages of Alzheimer's disease but are also associated with a risk of cerebral haemorrhages and oedema. The introduction of these antibodies will require adjustment of diagnostic and management pathways as discussed in this review.",

keywords = "Humans, Alzheimer Disease/drug therapy, Amyloid beta-Peptides/immunology, Antibodies, Monoclonal, Humanized/therapeutic use, Antibodies, Monoclonal/therapeutic use",

author = "Frederiksen, {Kristian Steen} and Gramkow, {Mathias Holsey} and Hasselbalch, {Steen G} and Ian Law and Gunhild Waldemar",

note = "Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.",

year = "2025",

month = aug,

day = "25",

doi = "10.61409/V03250217",

language = "Dansk",

volume = "187",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "35",

}

TY - JOUR

T1 - Antiamyloidantistoffer til behandling af Alzheimers sygdom i tidlige sygdomsstadier

AU - Frederiksen, Kristian Steen

AU - Gramkow, Mathias Holsey

AU - Hasselbalch, Steen G

AU - Law, Ian

AU - Waldemar, Gunhild

N1 - Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.

PY - 2025/8/25

Y1 - 2025/8/25

N2 - Alzheimer's disease is the most common neurodegenerative dementia disorder and is associated with several negative health outcomes. Current treatment consists of symptomatic treatment and supportive measures. However, advances have led to the development of antibodies towards beta-amyloid, which likely plays a pivotal role in the pathophysiology. Lecanemab and donanemab have shown efficacy in the early stages of Alzheimer's disease but are also associated with a risk of cerebral haemorrhages and oedema. The introduction of these antibodies will require adjustment of diagnostic and management pathways as discussed in this review.

AB - Alzheimer's disease is the most common neurodegenerative dementia disorder and is associated with several negative health outcomes. Current treatment consists of symptomatic treatment and supportive measures. However, advances have led to the development of antibodies towards beta-amyloid, which likely plays a pivotal role in the pathophysiology. Lecanemab and donanemab have shown efficacy in the early stages of Alzheimer's disease but are also associated with a risk of cerebral haemorrhages and oedema. The introduction of these antibodies will require adjustment of diagnostic and management pathways as discussed in this review.

KW - Humans

KW - Alzheimer Disease/drug therapy

KW - Amyloid beta-Peptides/immunology

KW - Antibodies, Monoclonal, Humanized/therapeutic use

KW - Antibodies, Monoclonal/therapeutic use

UR - http://www.scopus.com/inward/record.url?scp=105015513482&partnerID=8YFLogxK

U2 - 10.61409/V03250217

DO - 10.61409/V03250217

M3 - Review

C2 - 40910390

SN - 0041-5782

VL - 187

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 35

M1 - V03250217

ER -

Antiamyloidantistoffer til behandling af Alzheimers sygdom i tidlige sygdomsstadier

Abstract

Emneord

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater